Prnewswire·2025-12-03 12:30Core Insights - ADC Therapeutics announced updated data from the LOTIS-7 Phase 1b trial, showing ZYNLONTA® combined with glofitamab (COLUMVI®) achieved an 89.8% overall response rate (ORR) and a 77.6% complete response (CR) rate in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) [1][2] Company Overview - ADC Therapeutics is a global leader in antibody drug conjugates (ADCs), focusing on innovative treatments for patients with hematological malignancies [2] - The company is headquartered in Lausanne, Switzerland, with operations in London and New Jersey [2] Clinical Trial Highlights - The LOTIS-7 trial is designed to evaluate the safety and efficacy of ZYNLONTA in combination with various agents, including glofitamab, in patients with B-cell non-Hodgkin lymphoma [1] - As of November 17, 2025, 49 patients were efficacy-evaluable, with a minimum of 6 months follow-up [1] - The trial aims to complete enrollment of approximately 100 patients by the first half of 2026, with full data expected to be shared at a medical meeting and submitted for publication by the end of 2026 [1] Efficacy Data - The best overall response rate (ORR) was 89.8%, with 44 out of 49 patients responding [1] - The complete response (CR) rate was 77.6%, with 33 of the 38 patients who achieved CR remaining in that state at the data cutoff [1] - In the subgroup of 24 relapsed patients, the ORR was 100% and the CR rate was 91.7% [1] - Among 25 primary refractory patients, the ORR was 80% and the CR rate was 64% [1] Safety Profile - The combination treatment was generally well tolerated, with a manageable safety profile [1] - Grade 3 or higher treatment-emergent adverse events (TEAEs) included neutropenia (32.7%), GGT increased (16.3%), and anemia (10.2%) [1] - Cytokine release syndrome (CRS) occurred in 36.7% of patients, with varying severity across dose levels [1] Future Plans - The company plans to assess regulatory and compendia strategies for ZYNLONTA and its combinations [1] - ADC Therapeutics is also advancing a next-generation PSMA-targeting ADC, leveraging its expertise in ADC development [2]